BACKGROUND: As cefiderocol is increasingly being prescribed in clinical practice, it is critical that we understand key mechanisms contributing to acquired resistance to this agent. METHODS: We describe a patient with acute lymphoblastic leukemia and a New Delhi metallo-ß-lactamase (NDM)-5-producing Escherichia coli intra-abdominal infection in whom resistance to cefiderocol evolved approximately 2 weeks after the start of treatment. Through whole-genome sequencing (WGS), messenger RNA expression studies, and ethylenediaminetetraacetic acid inhibition analysis, we investigated the role of increased NDM-5 production and genetic mutations contributing to the development of cefiderocol resistance, using 5 sequential clinical E. coli isolates obtained from the patient. RESULTS: In all 5 isolates, blaNDM-5 genes were identified. The minimum inhibitory concentrations for cefiderocol were 2, 4, and >32 μg/mL for isolates 1-2, 3, and 4-5, respectively. WGS showed that isolates 1-3 contained a single copy of the blaNDM-5 gene, whereas isolates 4 and 5 had 5 and 10 copies of the blaNDM-5 gene, respectively, on an IncFIA/FIB/IncFII plasmid. These findings were correlated with those of blaNDM-5 messenger RNA expression analysis, in which isolates 4 and 5 expressed blaNDM-5 1.7- and 2.8-fold, respectively, compared to, isolate 1. Synergy testing with the combination of ceftazidime-avibactam and aztreonam demonstrated expansion of the zone of inhibition between the disks for all isolates. The patient was successfully treated with this combination and remained infection free 1 year later. CONCLUSIONS: The findings in our patient suggest that increased copy numbers of blaNDM genes through translocation events are used by Enterobacterales to evade cefiderocol-mediated cell death. The frequency of increased blaNDM-5 expression in contributing to cefiderocol resistance needs investigation.
BACKGROUND: As cefiderocol is increasingly being prescribed in clinical practice, it is critical that we understand key mechanisms contributing to acquired resistance to this agent. METHODS: We describe a patient with acute lymphoblastic leukemia and a New Delhi metallo-ß-lactamase (NDM)-5-producing Escherichia coli intra-abdominal infection in whom resistance to cefiderocol evolved approximately 2 weeks after the start of treatment. Through whole-genome sequencing (WGS), messenger RNA expression studies, and ethylenediaminetetraacetic acid inhibition analysis, we investigated the role of increased NDM-5 production and genetic mutations contributing to the development of cefiderocol resistance, using 5 sequential clinical E. coli isolates obtained from the patient. RESULTS: In all 5 isolates, blaNDM-5 genes were identified. The minimum inhibitory concentrations for cefiderocol were 2, 4, and >32 μg/mL for isolates 1-2, 3, and 4-5, respectively. WGS showed that isolates 1-3 contained a single copy of the blaNDM-5 gene, whereas isolates 4 and 5 had 5 and 10 copies of the blaNDM-5 gene, respectively, on an IncFIA/FIB/IncFII plasmid. These findings were correlated with those of blaNDM-5 messenger RNA expression analysis, in which isolates 4 and 5 expressed blaNDM-5 1.7- and 2.8-fold, respectively, compared to, isolate 1. Synergy testing with the combination of ceftazidime-avibactam and aztreonam demonstrated expansion of the zone of inhibition between the disks for all isolates. The patient was successfully treated with this combination and remained infection free 1 year later. CONCLUSIONS: The findings in our patient suggest that increased copy numbers of blaNDM genes through translocation events are used by Enterobacterales to evade cefiderocol-mediated cell death. The frequency of increased blaNDM-5 expression in contributing to cefiderocol resistance needs investigation.
Authors: Krystyna M Kazmierczak; Masakatsu Tsuji; Mark G Wise; Meredith Hackel; Yoshinori Yamano; Roger Echols; Daniel F Sahm Journal: Int J Antimicrob Agents Date: 2018-10-26 Impact factor: 5.283
Authors: David X Li; Anna C Sick-Samuels; Nuntra Suwantarat; Rebecca G Same; Patricia J Simner; Pranita D Tamma Journal: Infect Control Hosp Epidemiol Date: 2017-12-05 Impact factor: 3.254
Authors: Ryan K Shields; Alina Iovleva; Ellen G Kline; Akito Kawai; Christi L McElheny; Yohei Doi Journal: Clin Infect Dis Date: 2020-12-17 Impact factor: 9.079
Authors: M M Sfeir; J A Hayden; K A Fauntleroy; C Mazur; J K Johnson; P J Simner; S Das; M J Satlin; S G Jenkins; L F Westblade Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Akito Kawai; Christi L McElheny; Alina Iovleva; Ellen G Kline; Nicolas Sluis-Cremer; Ryan K Shields; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Sabrina Klein; Sébastien Boutin; Kaan Kocer; Mascha O Fiedler; Dominic Störzinger; Markus A Weigand; Benjamin Tan; Daniel Richter; Christian Rupp; Markus Mieth; Arianeb Mehrabi; Thilo Hackert; Stefan Zimmermann; Klaus Heeg; Dennis Nurjadi Journal: Clin Infect Dis Date: 2022-03-09 Impact factor: 9.079